Colorado Has Just Legalized The Use of Magic Mushrooms – Yahoo Finance

Vancouver, BC –News Direct– MarketJar
Psychoactive medicine has come a long way in the last couple of years and is not slowing down anytime soon. Gone are the days when hallucinogens conjured up images of tie-dye T-shirts and peace signs. The psychoactive renaissance taking place right now is fueled by governments, science, celebrities and big-time investors.
The worsening mental health and substance-abuse crises and the clear benefits of psychoactive-assisted therapy to combat these issues are becoming too big to ignore, creating an unstoppable shift in the way society views psychoactives.
Colorado, a pioneer in the recreational MJ space, just became the second state to decriminalize and legalize the use of psychoactives for recreational purposes.
Voters passed a ballot initiative during the mid-term election to make it legal for adults to purchase and use psychoactives.
Colorado’s bill is creating a domino effect. Right now there are at least 20 different US states and cities working towards decriminalizing the substances. And things could soon reach the federal level. In July, Joe Biden said that he expects regulators to approve psychoactives within the next two years to treat PTSD and depression.
Canada is also making strides in legalization. In October, Alberta made history by becoming the first province to regulate psychoactives for the treatment of mental health conditions. The Province’s new regulatory framework is due to take effect January 2023.
These changes in regulations come at a time when the national mental health crisis is worsening and in turn, more people are seeking help from alternative treatment providers. According to John Hopkins Medicine, 26% of Americans age 18 and over suffer from a diagnosable mental disorder in a given year, while over 6.7 million people in Canada struggle with mental health issues or illnesses.
As psychoactives gain more acceptance, companies within the market stand to benefit, particularly those offering high-quality products and integrated mental health care treatment options at clinics.
Leading integrated mental healthcare company Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF) is focused on the development and delivery of innovative mental health care and access to safe, evidence-based psychoactive-assisted therapies.
Numinus has continued to expand its mental health service offerings as well as its network of wellness clinics across Canada and the US.
Numinus has already experienced noteworthy revenue growth in Q3 2022, growing nearly 32% year-over-year (YoY), which was primarily driven by the acquisitions of the Neurology Centre of Toronto and Mindspace. The company also saw its gross margin grow by 24.4% in Q3, compared to -2.8% YoY. And with the acquisition of Novamind, which closed in June 2022, Numinus is now one of the highest revenue-producing mental healthcare companies providing psychoactive-assisted therapies, with over $12 million of combined proforma annual revenues.
The company will be releasing its fourth quarter 2022 results on November 29 and according to Numinus founder and CEO Payton Nyquvest, Q4 will be “the first quarter demonstrating the power of its larger, cross-border platform.”
Numinus Wellness also recently launched its Ketamine for Chronic and Serious Medical Illness Program. This new program will first be implemented in Numinus clinics in Utah, British Columbia, and Quebec. The company plans to expand the program to other clinics in the coming months.
Numinus’ program will include psychoactive-assisted therapy along with additional community support to alleviate patients’ physical, emotional, mental, and spiritual suffering and care from healthcare professionals who specialize in severe and chronic medical illnesses.
As Oregon and Colorado have now legalized psychoactives, the Biden administration is working to get psilocybin federally approved within the next two years as clinical evidence of their effectiveness in treating mental health disorders grows.
It’s only a matter of time and Numinus is ready for expansion. For more information on Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF) and how the company is leading the integration of psychoactive-assisted therapies into mainstream clinical practice, please visit this link.
1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.
2) The Article was issued on behalf of and sponsored by, Numinus Wellness Inc. Market Jar Media Inc. has or expects to receive from Numinus Wellness Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) one hundred nine thousand four hundred and forty USD for 23 days (16 business days).
3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.
4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on
5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.
6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Numinus Wellness Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Numinus Wellness Inc.’s industry; (b) market opportunity; (c) Numinus Wellness Inc.’s business plans and strategies; (d) services that Numinus Wellness Inc. intends to offer; (e) Numinus Wellness Inc.’s milestone projections and targets; (f) Numinus Wellness Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Numinus Wellness Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Numinus Wellness Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Numinus Wellness Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Numinus Wellness Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Numinus Wellness Inc.’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Numinus Wellness Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Numinus Wellness Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Numinus Wellness Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Numinus Wellness Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Numinus Wellness Inc.’s business operations (e) Numinus Wellness Inc. may be unable to implement its growth strategy; and (f) increased competition.
Except as required by law, Numinus Wellness Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Numinus Wellness Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Numinus Wellness Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.
7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Numinus Wellness Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Numinus Wellness Inc. or such entities and are not necessarily indicative of future performance of Numinus Wellness Inc. or such entities.
Market Jar Media Inc.
James Young
+1 800-340-9767
View source version on
Wedbush on Wednesday said it is removing Jack in the Box Inc. from its Best Ideas List but maintained its outperform rating on the restaurant chain. "We continue to believe JACK's current valuation discounts an overly pessimistic view of management's ability to successfully integrate the Deal Taco acquisition and to achieve unit growth acceleration and same-store sales growth over the longer-term across both brands," Wedbush said in a research note. Wedbush said until is sees incremental visibil
Many people are impacted by addiction, and the overdose crisis and illicit toxic drug supply continue to impact individuals, families and communities across our country. Raising awareness on addiction, reducing stigma related to substance use and providing a range of supports for people living with addiction and problematic substance use has never been more important.
CAPSLO to receive $5M grant from Bezos Day 1 Fund
(Bloomberg) — Investors are being sounded out by Warren Buffett’s Berkshire Hathaway Inc. about the sale of a potential multi-part yen bond offering, according to people with direct knowledge of the matter. Most Read from BloombergElizabeth Holmes Judge Proposes Texas Prison, Family VisitsAnwar to Test Majority With Malaysia Parliament Vote in DecemberBinance’s Zhao Flags Possible $1 Billion for Distressed AssetsChina Covid Cases Jump to Record High, Topping Shanghai OutbreakThe deal may includ
(Bloomberg) — Vista Equity Partners is exploring an acquisition of Coupa Software Inc., according to people familiar with the matter. The stock rose as much as 36% on the news. Most Read from BloombergElizabeth Holmes Judge Proposes Texas Prison, Family VisitsMost Fed Officials Seek to Slow Pace of Interest-Rate Hikes SoonChina Covid Cases Jump to Record High, Topping Shanghai OutbreakFrom Tom Brady to Shaq, FTX’s Celebrity Promoters May Be On the Hook for DamagesVista has held talks with the S
Concerns surrounding the growth of big tech do not apply to George Soros. The Federal Reserve's decision to aggressively raise interest rates to fight inflation, which is at a 40-year high, threatens to push the economy into a recession, many analysts say. This inflation, which is particularly impacting consumers, is a huge problem for the technology sector, because tech products and services are the first to suffer from spending cuts.
With a history of decades-long investing success, billionaire Ken Griffin knows a thing or two about market behavior. Recently, the Citadel Investment Group Founder and CEO offered some of his thoughts on the state of the stock market and where the economy is heading. While Griffin believes inflation has already peaked, he thinks the Fed has yet to truly put the “genie back in the bottle.” He also thinks unemployment is about to rise and expects a recession will likely materialize “sometime in t
What time does the stock market close the day before Thanksgiving? Is the stock market open on Black Friday?
Warren Buffett — the Oracle of Omaha — is widely regarded as one of the greatest investors of all time. Berkshire Hathaway Inc. (NYSE: BRK-A) has returned tens of thousands of percent over the years and consistently outperforms the market. Buffett purchased the company for just $8.3 million in 1965, and it’s now valued at nearly $700 billion, roughly a 10 million percent return. But one of Buffett’s top all-time picks and longest-held positions is one you might not expect. Berkshire Hathaway fir
FTX lawyers say a substantial amount of assets are missing or stolen in latest bankruptcy proceedings; Cathie Wood still sees Bitcoin at $1 million
Patience can pay off handsomely when you're invested in companies with clearly defined competitive advantages.
Amazon (NASDAQ: AMZN) is one of the best-performing stocks of the past generation, but 2022 has mostly been a disaster for the tech giant. The stock is down 47% year to date, revenue growth has slowed to all-time lows, it's closed dozens of warehouses after overestimating demand, shuttered once-promising projects like Amazon Care, and just reported that it's laying off 10,000 corporate employees. While it's clear Amazon has struggled this year, those challenges seem well-reflected in Amazon's stock price.
The word "hypergrowth" does not describe the current technology bear market. Such a change may point to buying opportunities in tech stocks such as SoFi Technologies (NASDAQ: SOFI) and Zscaler (NASDAQ: ZS). Amid the moratorium on student loan payments because of the pandemic, it had to pivot into other areas of finance.
Both of these stocks have great long-term prospects and offer an attractive dividend in the meantime.
In the early days of the pandemic, investors bet Novavax (NASDAQ: NVAX) would be a coronavirus vaccine winner. When the biotech's vaccine candidate fell behind, though, investors lost faith. With its shares down almost 90% this year, you may be wondering if Novavax presents a great buying opportunity.
This year has been tough for investors. The inflation numbers may have been down in October, but it was still 7.7% compounded on last October’s 6.2%, and that’s too high. Interest rates are rising fast in response, making capital more expensive, and the available cash is chasing goods constrained by tight supply chains and continued COVID lockdowns in China. Food and energy prices are high, and likely to rise, as Russia’s war in Ukraine puts a major clamp on global supplies of natural gas, wheat
Despite the fact that Advanced Micro Devices, Inc. (NASDAQ:AMD) stock rose 5.1% last week, insiders who sold US$4.1m…
Coupa Software (COUP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Even though mid-term election results and encouraging inflation news have pushed U.S. stocks to their highest levels since August, a prominent UBS analyst says a recession is due and the global economy will continue to decline and that markets will … Continue reading → The post UBS Analyst Says This Is When Investors Should Buy the Dip appeared first on SmartAsset Blog.
Instead of gearing up to trade Thursday, investors may be defrosting their Thanksgiving turkeys—and clipping coupons ahead of Black Friday.


Sharing Is Caring:

Leave a Comment